Autoimmune and Inflammatory Diseases
Accelerating Therapies for Immune-Mediated Diseases
Autoimmune and inflammatory diseases arise from complex interactions between innate and adaptive immunity, cytokine signaling, genetic susceptibility, and tissue-specific immune responses. Models that faithfully reproduce disease biology and provide clinically predictive translational biomarkers are the cornerstone of developing effective therapies.
WuXi Biology and Testing supports discovery programs across autoimmune, inflammatory, and immune-mediated diseases through integrated target discovery, in vitro and in vivo pharmacology, translational biomarker analysis, DMPK, bioanalysis, and safety assessment. Our platforms support multiple therapeutic modalities including small molecules, antibodies, conjugates (e.g., ADC), peptides, oligonucleotides, and other advanced therapeutics from early discovery through IND-enabling studies.
Autoimmune & Inflammatory Drug Discovery
From Immune Biology to Clinical Translation
Autoimmune & inflammatory drug discovery is complicated by pathway redundancy, patient heterogeneity, tissue-specific immune responses, and differences between preclinical models and human disease. Addressing these challenges requires complementary cellular systems, translational disease models, PK/PD evaluation, and biomarker strategies.
We combine disease-relevant cellular systems, translational animal models, PK/PD evaluation, biomarker analysis, and regulatory toxicology to generate data that supports confident candidate selection while reducing development risk.
Stage-Based Challenges and Solutions
Challenges
Identifying compounds that selectively modulate immune pathways while minimizing off-target immunosuppression.
Solutions
- Target identification and validation
- Biochemical and cellular immune assays
- Cytokine profiling
- Phenotypic screening
- Hit identification and lead optimization
Challenges
Selecting relevant targets and demonstrating mechanism of action for antibodies, bispecifics, and nucleic acid therapeutics.
Solutions
- Human immune cell assays
- Receptor occupancy and target engagement
- Internalization assays
- Functional immune-cell activation assays
- Biomarker identification
Challenges
Demonstrating efficacy in disease models that reproduce human inflammatory mechanisms.
Solutions
- Acute inflammation models
- Skin disease models
- Systemic disease models
- Rheumatic disease models
- Gastrointestinal disease models (e.g., IBD)
- Neuroinflammation disease models
- Respiratory models
- PK/PD and efficacy studies
Challenges
Evaluating therapies in specialized models with clinically relevant endpoints.
Solutions
- Rare immunological disease models
- Customized genetically engineered models
- Colony management
- Biomarker assessment
- Translational pharmacology
Challenges
Characterizing pharmacokinetics, target engagement, immunogenicity, and pharmacodynamic response for biologics and targeted conjugates while supporting clinical translation.
Solutions
- Pharmacokinetic (PK) and biodistribution studies
- Ligand binding bioanalysis
- Anti-drug antibody (ADA) and immunogenicity testing
- Receptor occupancy and PD biomarker assays
- PK/PD modeling and dose projection
Challenges
Optimizing pharmacokinetics, tissue exposure, and pharmacodynamic activity while maintaining efficacy, selectivity, and an appropriate safety profile.
Solutions
- In vitro ADME profiling
- Pharmacokinetic studies
- Metabolite identification
- Drug-drug interaction assessment
- LC-MS/MS bioanalysis
- PK/PD relationship assessment
Challenges
Evaluating safety, immunogenicity, and target-related toxicities while supporting the development of biologics and targeted conjugates for chronic immune-mediated diseases.
Solutions
- Immunogenicity (ADA) assessment
- Cytokine and immune safety biomarkers
- Target organ toxicity evaluation
- GLP toxicology studies
- Tissue cross-reactivity and histopathology
- IND-enabling safety support
Challenges
Establishing a comprehensive safety profile while optimizing therapeutic index, minimizing off-target effects, and supporting chronic administration.
Solutions
- Repeat-dose GLP toxicology studies
- Safety pharmacology
- Genotoxicity and investigative toxicology
- ADME/TK integration
- Clinical pathology and histopathology
- IND-enabling safety support0
Disease Models for Autoimmune and Inflammatory Research
Autoimmune and inflammatory diseases are driven by complex immune responses that vary across tissues, disease stages, and patient populations. Understanding both immune dysregulation and chronic inflammation requires disease-relevant models that capture inflammatory signaling, immune cell interactions, and tissue pathology. WuXi Biology and Testing provides an integrated portfolio of in vitro, ex vivo, and in vivo autoimmune and inflammatory disease models to evaluate mechanism of action, efficacy, and translational biomarkers across diverse indications.
Capabilities include:
- Immune cell activation and functional assays
- Inflammatory cytokine and pathway models
- Primary immune cell and co-culture systems
- Human organoids and 3D disease models
- Ex vivo tissue models
- Acute and chronic autoimmune and inflammatory disease models
- Neuroinflammation, respiratory inflammation, dermatology, gastrointestinal inflammation, and rare autoimmune disease models
- Translational pharmacology and efficacy studies
Translational Biomarkers of Immune Activation and Inflammation
Demonstrating therapeutic activity requires more than measuring efficacy alone. Biomarkers of immune activation, inflammatory signaling, and tissue response help confirm target engagement, characterize pharmacodynamic effects, and support translation from preclinical studies into the clinic. Our integrated pharmacology and bioanalytical platforms generate comprehensive molecular, cellular, and histopathological datasets to accelerate confident decision-making.
Capabilities include:
- Cytokine and chemokine profiling
- Immune cell phenotyping by flow cytometry
- Receptor occupancy and target engagement biomarkers
- Multiplex immunoassays
- Histopathology and digital pathology
- Immunohistochemistry (IHC) and multiplex immunofluorescence
- Gene and protein expression analysis
- PK/PD biomarker integration
Therapeutic Modalities for Immune-Mediated Diseases
The treatment landscape for autoimmune and inflammatory diseases has rapidly expanded beyond conventional small molecules to include biologics, targeted conjugates, RNA, and other advanced therapeutics. We integrate discovery biology, pharmacology, DMPK, bioanalysis, and safety assessment to support the development of therapies that modulate immune responses, control inflammation, and restore tissue homeostasis from discovery through IND-enabling studies.
Supported modalities include:
- Small molecules
- Monoclonal and bispecific antibodies
- Fusion proteins
- Antibody-drug conjugates (ADCs)
- Antibody-oligonucleotide conjugates (AOCs)
- Peptide-drug conjugates (PDCs)
- Peptides
- RNA therapeutics (siRNA, ASOs, mRNA)
Related Services
Discovery Biology
Integrated discovery platforms supporting target discovery, pharmacology, disease models, and translational biology.
Learn More
DMPK
ADME, pharmacokinetics, PK/PD, and drug disposition studies for biologics and small molecules.
Learn More
Bioanalysis
Quantitative bioanalysis, biomarker testing, ligand binding assays, and immunogenicity assessment.
Learn More
Safety Assessment
GLP toxicology, safety pharmacology, and IND-enabling studies supporting regulatory submissions.
Learn More
You May Also Be Interested In
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.
Frequently Asked Questions
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, while inflammatory diseases are characterized by excessive or chronic inflammation that can damage organs and tissues. Since clinical conditions frequently involve overlapping pathways of immune dysregulation and chronic inflammation, they represent highly complex targets for drug discovery, requiring sophisticated models to study and treat effectively.
These diseases are driven by complex networks of immune cells, redundant signaling pathways, and high patient heterogeneity influenced by genetic and environmental factors. This profound biological complexity makes it challenging to identify definitive therapeutic targets, predict treatment responses, and develop therapies that achieve an optimal balance of durable efficacy and safety.
Treatment strategies continue to evolve beyond traditional small molecules to include monoclonal antibodies, bispecific antibodies, fusion proteins, targeted conjugates, RNA, and other advanced therapeutics. The selection of modality is guided by disease biology, target characteristics, and clinical endpoints.
Researchers typically study disease mechanisms using a mix of in vitro immune cell assays, organoids, ex vivo tissues, and animal models., evaluate therapeutic efficacy, and identify translational biomarkers. Using complementary models helps improve confidence in preclinical findings before clinical development.
Biomarkers help researchers measure target engagement, immune activation, inflammatory responses, and pharmacodynamic effects. They support candidate selection, dose optimization, and translation from preclinical studies to clinical trials, improving decision-making throughout drug development.
Our platforms support a broad range of autoimmune and inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, multiple sclerosis, asthma, chronic obstructive pulmonary disease, atopic dermatitis, neuroinflammation, vitiligo, alopecia, Sjögren’s syndrome, ankylosing spondylitis, and rare immune-mediated disorders. Customized disease models are also available.
We combine cellular immunology assays, cytokine profiling, flow cytometry, multiplex biomarker analysis, histopathology, molecular biology, and translational animal models to evaluate efficacy, mechanism of action, and pharmacodynamic response.
Yes. Our integrated platform combines discovery biology with DMPK, bioanalysis, PK/PD modeling, biomarker testing, immunogenicity assessment, and GLP safety studies to support programs from hit identification through IND-enabling development.